kiniksa
announces
positive
data
phase
trial
mavrilimumab
giant
cell
arteritis
hamilton
bermuda
globe
newswire
kiniksa
pharmaceuticals
nasdaq
knsa
kiniksa
biopharmaceutical
company
pipeline
assets
designed
modulate
immunological
pathways
across
spectrum
diseases
announced
positive
data
global
phase
trial
mavrilimumab
giant
cell
arteritis
gca
mavrilimumab
investigational
monoclonal
antibody
targets
granulocyte
macrophage
colony
stimulating
factor
receptor
alpha
trial
achieved
primary
secondary
efficacy
endpoints
statistical
significance
thrilled
report
primary
secondary
efficacy
endpoints
phase
trial
mavrilimumab
giant
cell
arteritis
achieved
statistical
significance
said
sanj
patel
chief
executive
officer
chairman
board
kiniksa
data
suggest
mavrilimumab
may
offer
treatment
option
patients
suffering
giant
cell
arteritis
demonstrate
potential
broad
utility
mavrilimumab
look
forward
presenting
additional
data
study
publication
future
medical
randomized
global
phase
trial
consists
screening
period
treatment
period
washout
safety
period
patients
age
years
active
gca
confirmed
temporal
artery
biopsy
imaging
erythrocyte
sedimentation
rate
esr
mm
hour
protein
crp
mg
dl
symptoms
gca
within
weeks
randomization
included
patients
required
achieved
remission
resolution
symptoms
esr
mm
hour
crp
mg
dl
prior
randomization
seventy
patients
randomized
mavrilimumab
mg
placebo
biweekly
injected
subcutaneously
oral
corticosteroid
taper
patients
stratified
new
onset
relapsing
refractory
disease
investigators
maria
cid
hospital
cl√≠nic
university
barcelona
idibaps
sebastian
unizony
massachusetts
general
hospital
harvard
university
primary
efficacy
endpoint
adjudicated
gca
flare
week
treated
patients
statistically
significant
hazard
ratio
median
week
could
estimated
mavrilimumab
recipients
due
low
number
flares
mavrilimumab
treatment
arm
median
placebo
recipients
weeks
lower
risk
flare
mavrilimumab
recipients
compared
placebo
recipients
secondary
efficacy
endpoint
sustained
remission
week
treated
patients
also
statistically
significant
sustained
remission
rate
week
percentage
points
higher
mavrilimumab
recipients
compared
placebo
recipients
mavrilimumab
serious
adverse
events
rates
adverse
events
mavrilimumab
recipients
placebo
recipients
similar
washout
safety
period
additional
analyses
phase
trial
ongoing
next
steps
development
program
gca
informed
anticipated
discussions
food
drug
administration
fda
believe
significant
unmet
need
safe
effective
giant
cell
arteritis
therapies
given
approximately
half
patients
achieve
sustained
remission
yearly
basis
current
standard
care
said
john
paolini
md
phd
chief
medical
officer
kiniksa
novel
therapies
safely
provide
sustained
remission
aging
patient
population
comorbidities
needed
mavrilimumab
upstream
inhibition
two
immune
pathways
implicated
giant
cell
arteritis
potential
provide
differentiation
addressing
underlying
pathophysiology
preclinical
data
previously
shown
scientific
conferences
available
science
section
kiniksa
website
support
mechanistic
rationale
targeting
granulocyte
macrophage
colony
stimulating
factor
pathway
upstream
patients
gca
downstream
helper
type
h
cell
helper
type
h
cell
pathways
demonstrated
activated
ribonucleic
acid
protein
level
arteries
gca
patients
compared
healthy
controls
mavrilimumab
demonstrated
inhibit
production
inflammatory
molecules
characteristic
gca
pathophysiology
ex
vivo
culture
model
arteries
gca
additionally
vivo
model
human
gca
mavrilimumab
reduced
arterial
inflammation
gamma
interferon
fda
recently
granted
orphan
drug
designation
mavrilimumab
treatment
gca
kiniksa
also
evaluating
mavrilimumab
severe
pneumonia
hyperinflammation
enrolling
phase
portion
global
randomized
adaptive
design
phase
clinical
trial
additionally
data
expected
randomized
study
fourth
quarter
poster
presentation
european
congress
rheumatology
eular
pathway
signature
identified
temporal
artery
biopsies
patients
giant
cell
arteritis
maria
cid
rohan
gandhi
marc
nekane
sujatha
muralidharan
john
paolini
presentation
american
college
rheumatology
acr
cytokine
experimental
vasculitis
medium
large
arteries
ryu
watanabe
hui
zhang
toshihisa
maeda
mitsuhiro
akiyama
rohan
gandhi
john
paolini
gerald
berry
cornelia
weyand
giant
cell
arteritis
giant
cell
arteritis
rare
chronic
inflammatory
disease
arteries
cranial
giant
cell
arteritis
typically
presents
headache
jaw
claudication
well
constitutional
symptoms
fever
fatigue
acute
events
include
permanent
vision
loss
diminished
blood
flow
eye
large
vessel
form
giant
cell
arteritis
affects
branches
aorta
supplying
trunk
limbs
currently
one
treatment
giant
cell
arteritis
adjunct
corticosteroid
taper
mavrilimumab
mavrilimumab
investigational
monoclonal
antibody
targets
mavrilimumab
dosed
patients
rheumatoid
arthritis
phase
clinical
studies
europe
achieved
primary
endpoints
efficacy
safety
kiniksa
lead
indication
mavrilimumab
gca
rare
inflammatory
disease
arteries
kiniksa
also
evaluating
mavrilimumab
pneumonia
hyperinflammation
fda
granted
orphan
drug
designation
mavrilimumab
gca
kiniksa
kiniksa
biopharmaceutical
company
focused
discovering
acquiring
developing
commercializing
therapeutic
medicines
patients
suffering
debilitating
diseases
significant
unmet
medical
need
kiniksa
product
candidates
rilonacept
mavrilimumab
vixarelimab
based
strong
biologic
rationale
validated
mechanisms
target
underserved
conditions
offer
potential
differentiation
pipeline
assets
designed
modulate
immunological
pathways
across
spectrum
diseases
information
please
visit
statements
information
contained
press
release
contains
statements
within
meaning
private
securities
litigation
reform
act
cases
identify
forward
looking
statements
terms
may
expect
plan
anticipate
could
intend
target
project
contemplate
believe
estimate
predict
potential
continue
negative
terms
similar
expressions
although
statements
contain
identifying
words
statements
contained
press
release
relate
matters
historical
fact
considered
statements
including
without
limitation
statements
regarding
mavrilimumab
potential
offer
treatment
option
patients
giant
cell
arteritis
potential
broad
utility
mavrilimumab
unmet
need
patients
gca
mavrilimumab
potential
address
underlying
pathophysiology
disease
presentation
additional
data
study
publication
future
medical
conference
anticipated
discussions
fda
development
program
gca
potential
impact
next
steps
program
timing
data
clinical
trials
potential
clinical
stage
product
candidates
offer
differentiation
statements
based
management
current
expectations
statements
neither
promises
guarantees
involve
known
unknown
risks
uncertainties
important
factors
may
cause
actual
results
performance
achievements
materially
different
future
results
performance
achievements
expressed
implied
statements
including
without
limitation
following
impact
additional
data
us
studies
companies
potential
undesirable
side
effects
caused
mavrilimumab
potential
inability
replicate
later
clinical
trials
positive
results
earlier
studies
clinical
trials
impact
discussions
fda
development
program
gca
reliance
third
parties
manufacture
product
candidates
conduct
clinical
trials
perform
certain
regulatory
activities
product
candidates
drug
substance
drug
product
shortages
engagement
manufacturing
organization
produce
mavrilimumab
beyond
current
inventory
potential
impact
pandemic
measures
taken
response
pandemic
changes
operating
plan
funding
requirements
existing
new
competition
ability
attract
retain
qualified
personnel
important
factors
discussed
caption
risk
factors
quarterly
report
form
filed
securities
exchange
commission
sec
august
reports
subsequently
filed
furnished
sec
could
cause
actual
results
differ
materially
indicated
statements
made
press
release
statements
represent
management
estimates
date
press
release
may
elect
update
statements
point
future
disclaim
obligation
even
subsequent
events
cause
views
change
statements
relied
upon
representing
views
date
subsequent
date
press
release
every
second
counts
kiniksa
investor
media
contact
mark
ragosa
mragosa
